237 related articles for article (PubMed ID: 20006455)
1. Efficacy and safety of lanthanoids as X-ray contrast agents.
Pietsch H; Jost G; Frenzel T; Raschke M; Walter J; Schirmer H; Hütter J; Sieber MA
Eur J Radiol; 2011 Nov; 80(2):349-56. PubMed ID: 20006455
[TBL] [Abstract][Full Text] [Related]
2. The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis - a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide.
Steger-Hartmann T; Raschke M; Riefke B; Pietsch H; Sieber MA; Walter J
Exp Toxicol Pathol; 2009 Nov; 61(6):537-52. PubMed ID: 19131226
[TBL] [Abstract][Full Text] [Related]
3. Tissue gadolinium deposition in renally impaired rats exposed to different gadolinium-based MRI contrast agents: evaluation with inductively coupled plasma mass spectrometry (ICP-MS).
Sato T; Ito K; Tamada T; Kanki A; Watanabe S; Nishimura H; Tanimoto D; Higashi H; Yamamoto A
Magn Reson Imaging; 2013 Oct; 31(8):1412-7. PubMed ID: 23643157
[TBL] [Abstract][Full Text] [Related]
4. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media.
Sieber MA; Pietsch H; Walter J; Haider W; Frenzel T; Weinmann HJ
Invest Radiol; 2008 Jan; 43(1):65-75. PubMed ID: 18097279
[TBL] [Abstract][Full Text] [Related]
5. Effects of gadolinium contrast agents in naïve and nephrectomized rats: relevance to nephrogenic systemic fibrosis.
Grant D; Johnsen H; Juelsrud A; Løvhaug D
Acta Radiol; 2009 Mar; 50(2):156-69. PubMed ID: 19160079
[TBL] [Abstract][Full Text] [Related]
6. Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents.
Pietsch H; Lengsfeld P; Steger-Hartmann T; Löwe A; Frenzel T; Hütter J; Sieber MA
Invest Radiol; 2009 Apr; 44(4):226-33. PubMed ID: 19252439
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the role of zinc in the occurrence of fibrosis of the skin: a preclinical study.
Pietsch H; Pering C; Lengsfeld P; Walter J; Steger-Hartmann T; Golfier S; Frenzel T; Hütter J; Weinmann HJ; Sieber MA
J Magn Reson Imaging; 2009 Aug; 30(2):374-83. PubMed ID: 19629978
[TBL] [Abstract][Full Text] [Related]
8. Lanthanide chelates of (bis)-hydroxymethyl-substituted DTTA with potential application as contrast agents in magnetic resonance imaging.
Silvério S; Torres S; Martins AF; Martins JA; André JP; Helm L; Prata MI; Santos AC; Geraldes CF
Dalton Trans; 2009 Jun; (24):4656-70. PubMed ID: 19513474
[TBL] [Abstract][Full Text] [Related]
9. The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats.
Pietsch H; Raschke M; Ellinger-Ziegelbauer H; Jost G; Walter J; Frenzel T; Lenhard D; Hütter J; Sieber MA
Invest Radiol; 2011 Jan; 46(1):48-56. PubMed ID: 20938346
[TBL] [Abstract][Full Text] [Related]
10. Nephrogenic systemic fibrosis in rats treated with erythropoietin and intravenous iron.
Hope TA; High WA; Leboit PE; Chaopathomkul B; Rogut VS; Herfkens RJ; Brasch RC
Radiology; 2009 Nov; 253(2):390-8. PubMed ID: 19789237
[TBL] [Abstract][Full Text] [Related]
11. Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure.
Fretellier N; Bouzian N; Parmentier N; Bruneval P; Jestin G; Factor C; Mandet C; Daubiné F; Massicot F; Laprévote O; Hollenbeck C; Port M; Idée JM; Corot C
Toxicol Sci; 2013 Jan; 131(1):259-70. PubMed ID: 22977165
[TBL] [Abstract][Full Text] [Related]
12. Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand.
Sieber MA; Lengsfeld P; Walter J; Schirmer H; Frenzel T; Siegmund F; Weinmann HJ; Pietsch H
J Magn Reson Imaging; 2008 May; 27(5):955-62. PubMed ID: 18425843
[TBL] [Abstract][Full Text] [Related]
13. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis.
Abraham JL; Thakral C; Skov L; Rossen K; Marckmann P
Br J Dermatol; 2008 Feb; 158(2):273-80. PubMed ID: 18067485
[TBL] [Abstract][Full Text] [Related]
14. Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis--an autopsy-based review.
Sanyal S; Marckmann P; Scherer S; Abraham JL
Nephrol Dial Transplant; 2011 Nov; 26(11):3616-26. PubMed ID: 21441397
[TBL] [Abstract][Full Text] [Related]
15. Identification and quantification of potential metabolites of Gd-based contrast agents by electrochemistry/separations/mass spectrometry.
Telgmann L; Faber H; Jahn S; Melles D; Simon H; Sperling M; Karst U
J Chromatogr A; 2012 Jun; 1240():147-55. PubMed ID: 22525874
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis of nephrogenic systemic fibrosis by means of elemental bioimaging and speciation analysis.
Birka M; Wentker KS; Lusmöller E; Arheilger B; Wehe CA; Sperling M; Stadler R; Karst U
Anal Chem; 2015 Mar; 87(6):3321-8. PubMed ID: 25708271
[TBL] [Abstract][Full Text] [Related]
17. In an animal model nephrogenic systemic fibrosis cannot be induced by intraperitoneal injection of high-dose gadolinium based contrast agents.
Langer RD; Lorke DE; Neidl van Gorkom KF; Petroianu G; Azimullah S; Nurulain SM; Singh S; Fuchsjäger M
Eur J Radiol; 2012 Oct; 81(10):2562-7. PubMed ID: 22304979
[TBL] [Abstract][Full Text] [Related]
18. Manipulation of reaction pathways in redox transmetallation-ligand exchange syntheses of lanthanoid(II)/(III) aryloxide complexes.
Deacon GB; Fallon GD; Forsyth CM; Harris SC; Junk PC; Skelton BW; White AH
Dalton Trans; 2006 Feb; (6):802-12. PubMed ID: 16437175
[TBL] [Abstract][Full Text] [Related]
19. NSF evaluation of gadolinium biodistribution in renally impaired rats: Using novel metabolic Gd2O3 nanoparticles coated with β-cyclodextrin (Gd2O3@PCD) in MR molecular imaging.
Ashouri H; Riyahi Alam N; Khoobi M; Haghgoo S; Rasouli Z; Gholami M
Magn Reson Imaging; 2024 Apr; 107():120-129. PubMed ID: 38215955
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and stability of caldiamide sodium in rats.
Okazaki O; Kurata T; Yoshioka N; Hakusui H
Arzneimittelforschung; 1996 Jan; 46(1):79-83. PubMed ID: 8821523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
